Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

GATA2 -Dependent Developmental and Regenerative Networks

Alexandra Soukup, PhD, Kirby D Johnson, PhD, Daniel J Conn, PhD, Evgenia Shishkova, PhD, Koichi Ricardo Katsumura, MD PhD, Peng Liu, PhD, Erik A. Ranheim, MD PhD, Katherine R. Calvo, MD PhD, Amy P. Hsu, Steven M. Holland, MD, Joshua J Coon, PhD, Sunduz Keles, PhD, Emery H Bresnick, PhD

Blood (2019) 134 (Supplement_1): 1182.

https://doi.org/10.1182/blood-2019-126875

Published: 2019

Journal Articles

Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): High Efficacy of High Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC auto-SCT). A Study of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Saad Akhtar, MD, Silvia Montoto, MD, Ariane Boumendil, PhD, Luca Castagna, MD, Herve Finel, Tamas Masszi, MD, Pavel Jindra, MD PhD, Damir Nemet, MD PhD, Herrad Baurmann, MD, Yves Beguin, MD PhD, Felicetto Ferrara, Saveria Capria, MD, Ram Malladi, MD PhD, Jose M Moraleda, MD PhD, Gilles Salles, MD PhD, Adrian Bloor, Julia Meissner, MD, Anna Sureda, MD, Peter Dreger, MD

Blood (2016) 128 (22): 514.

https://doi.org/10.1182/blood.V128.22.514.514

Published: 2016

Journal Articles

Role of Consolidation High Dose Chemotherapy (HDC) with Autologous Stem Cell Transplant (ASCT) Support in Patients with Peripheral T-Cell Lymphoma Who Achieved Complete Remission (CR1) Following First Line Induction Chemotherapy

Lay Poh Khoo, BSc, Tiffany Tang, MD, Suk Teng Chin, BSc, Jeslin Ha, BSc, Colin Phipps, MBBS, MRCP, FRCPath, Yuh Shan Lee, MBBS, MRCP, FRCPath, Mohamad Farid, MD, Kevin Tay, MD, Miriam Tao, MD, Richard Hong Hui Quek, MD, Soon Thye Lim, MD

Blood (2016) 128 (22): 4640.

https://doi.org/10.1182/blood.V128.22.4640.4640

Published: 2016

Journal Articles

Double Epigenetic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma

Yago Nieto, MD, PhD, Benigno C. Valdez, PhD, Peter F Thall, PhD, Wei Wei, MS, Roy Jones, MD PhD, Chitra M. Hosing, MD, Sairah Ahmed, MD, Uday R. Popat, MD, Elizabeth J. Shpall, MD, Muzaffar Qazilbash, MD, Alison M Gulbis, Paolo Anderlini, MD, Nina Shah, MD, Qaiser Bashir, MD, Amin M. Alousi, MD, Yasuhiro Oki, MD, Fredrick B. Hagemeister, MD, Richard E. Champlin, MD, Borje S. Andersson, MD PhD

Blood (2015) 126 (23): 1992.

https://doi.org/10.1182/blood.V126.23.1992.1992

Published: 2015

Journal Articles

GATA2 Expression Level in Chronic Myeloid Leukemia (CML) Patients Correlates with Their Prognostic Scores and Is Associated with Disease Stage at Diagnosis

Philippe Guardiola, MD, Corentin Orvain, Nick C.P. Cross, PhD, Martine Gardembas, MD, Marc Spentchian, MD, Estelle Pedrono, PhD, Diane Lambert, PhD, Anne Coutolleau, Anne Bouvier, MD, Odile Blanchet, MDPhD, Nicole Piard, MD, Norbert Ifrah, MD PhD, Frank Giles, MD MB, FRCPI, FRCPath, Andreas Hochhaus, MD, Jerald P. Radich, MD, Philippe Rousselot, MD PhD

Blood (2015) 126 (23): 2768.

https://doi.org/10.1182/blood.V126.23.2768.2768

Published: 2015

Journal Articles

R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma

Antonio Omuro, Denise D. Correa, Lisa M. DeAngelis, Craig H. Moskowitz, Matthew J. Matasar, Thomas J. Kaley, Igor T. Gavrilovic, Craig Nolan, Elena Pentsova, Christian C. Grommes, Katherine S. Panageas, Raymond E. Baser, Geraldine Faivre, Lauren E. Abrey, Craig S. Sauter

Blood (2015) 125 (9): 1403–1410.

https://doi.org/10.1182/blood-2014-10-604561

Published: 2015

Includes: Supplemental data

Journal Articles

Intense Cytarabine-Based Chemo-Immunotherapy, Central Nervous System (CNS) Prophylaxis and Early High-Dose Chemotherapy and Autologous Stem Cell Support (HDC-ASCS) in First Remission Are Associated with an Improved Clinical Outcome in Double-Hit (DHL)/Triple-Hit (THL) Diffuse Large B-Cell Lymphoma (DLBCL)

Priyank P. Patel, MD, Pallawi Torka, MD, Vishala T. Neppalli, MD, George Deeb, MD, Sheila N.J. Sait, PhD, AnneMarie W. Block, PhD, Seema A. Bhat, MD, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2014) 124 (21): 3031.

https://doi.org/10.1182/blood.V124.21.3031.3031

Published: 2014

Journal Articles

Brentuximab Vedotin (BV) Does Not Impair Autologous Peripheral Blood Stem Cell Mobilization and Collection in Refractory/Relapsed CD30+ Lymphoma Patients Undergoing High-Dose Chemotherapy and Autologous Stem Cell Transplant (HDC-ASCT)

Manuel Afable, BSN, MD, Paolo F. Caimi, MD, Chitra Hosing, Marcos de Lima, MD, Issa F. Khouri, MD, Basem M. William, MD, Yago Nieto, MD PhD, Brenda W. Cooper, MD, Paolo Anderlini, MD, Erica L Campagnaro, MD, Stanton L. Gerson, Hillard M. Lazarus, MD, Richard E. Champlin, Uday R. Popat, MD

Blood (2014) 124 (21): 3854.

https://doi.org/10.1182/blood.V124.21.3854.3854

Published: 2014

Journal Articles

Voriconazole (VRCZ) Versus Itraconazole (ITCZ) As Antifungal Prophylaxis For Acute Myelogenus Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Patients In Induction Therapy, Prospective Randomized Study

Kouhei Kyo, M.D., Mitsuhiro Itagaki, MD, Taiichi Kyo, MD, Takeshi Okatani, M.D., Tetsuro Ochi, Yuta Katayama, MD, PhD, Ryouta Imanaka, M.D., Kouji Iwato, Hideki Asaoku, M.D.

Blood (2013) 122 (21): 3897.

https://doi.org/10.1182/blood.V122.21.3897.3897

Published: 2013

Journal Articles

Natural killer–cell differentiation by myeloid progenitors

Bartosz Grzywacz, Nandini Kataria, Niketa Kataria, Bruce R. Blazar, Jeffrey S. Miller, Michael R. Verneris

Blood (2011) 117 (13): 3548–3558.

https://doi.org/10.1182/blood-2010-04-281394

Published: 2011

Includes: Supplemental data

Journal Articles

Gemcitabine, Busulfan and Melphalan (GemBuMel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity In Refractory Hodgkin's Lymphoma (HL) Patients Receiving An Autologous Stem-Cell Transplant (ASCT): A Contemporaneous Comparison with BEAM and Busulfan/Melphalan (BuMel)

Yago Nieto, MD, Paolo Anderlini, MD, Uday Popat, MD, Ping Liu, MS, Borje S Andersson, MD, PhD, Elizabeth J. Shpall, MD, Partow Kebriaei, MD, Chitra Hosing, MD, Amin M Alousi, MD, Muzaffar H. Qazilbash, MD, Stefan O. Ciurea, MD, Simrit Parmar, MD, Richard E. Champlin, MD, Roy Jones, PhD, MD

Blood (2010) 116 (21): 690.

https://doi.org/10.1182/blood.V116.21.690.690

Published: 2010

Journal Articles

Blastoid Variant of Mantle Cell Lymphoma (MCL) Is Associated with P53 Abnormalities and Have a Shorter Progression-Free Survival (PFS) and Overall Survival (OS) Despite Upfront Chemo-Immunotherapy Followed by High Dose Chemotherapy and Autologous Stem Cell Support (HDC-ASCS)

Lyudmyla Derby, MD, Gopichand Pendurti, MD, George Deeb, MD, Sheila Sait, PhD, Annmarie Block, PhD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2010) 116 (21): 1773.

https://doi.org/10.1182/blood.V116.21.1773.1773

Published: 2010

Journal Articles

Mantle Cell International Prognostic Index (MIPI) Is a Strong Predictor of the Outcome of Mantle Cell Lymphoma (MCL) in the Rituximab (R) Era.

Annalisa Chiappella, Benedetta Puccini, Marianna Rossi, Simone Ferrero, Luca Arcaini, Ernesta Audisio, Ileana Baldi, Carola Boccomini, Barbara Botto, Fabbri Alberto, Chiara Frairia, Roberto Freilone, Marco Ladetto, Domenico Novero, Marco Paulli, Patrizia Pregno, Giorgio Priolo, Luigi Rigacci, Umberto Vitolo

Blood (2009) 114 (22): 2928.

https://doi.org/10.1182/blood.V114.22.2928.2928

Published: 2009

Journal Articles

The Effects of Rituximab Added to Front-Line or Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing High-Dose Chemotherapy (HDC) and Autologous Stem Cell Transplant (ASCT).

Umeer Ashraf, MD, Ritika Mahajan, MBBS, Theresa Hahn, PhD, Shannon L Smiley, MD, Philip L. McCarthy, MD, Zale P. Bernstein, MD, Asher Alban Chanan-Khan, MD, Minoo Battiwala, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2008) 112 (11): 1138.

https://doi.org/10.1182/blood.V112.11.1138.1138

Published: 2008

Journal Articles

Activated B-Cell (ABC) Profile Does Not Have An Inferior Outcome Compared to Germinal Center B-Cell (GCB) Profile Determined by Immunohistochemistry Tissue Microarray in Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and Dose- Dense and High-Dose Chemotherapy (HDC) Plus Autologous Stem Cell Transplantation (ASCT).

Blood (2008) 112 (11): 1139.

https://doi.org/10.1182/blood.V112.11.1139.1139

Published: 2008

Journal Articles

Identification of a Myeloid Pathway of NK Cell Development and a Myeloid- NK Cell Precursor

Bartosz Grzywacz, MD, Nandini Kataria, BS, Bruce R. Blazar, MD, Jeffrey S. Miller, MD, Michael Verneris, MD

Blood (2008) 112 (11): 103.

https://doi.org/10.1182/blood.V112.11.103.103

Published: 2008

Journal Articles

Validation of Mantle Cell International Prognostic Index (MIPI) in Mantle Cell Lymphoma (MCL) in a Retrospective Single Institution Series

Annalisa Chiappella, Barbara Botto, Filippo Marmont, Ernesta Audisio, Ileana Baldi, Giulia Benevolo, Carola Boccomini, Stefano D’Ardia, Chiara Frairia, Roberto Freilone, Lorella Orsucci, Patrizia Pregno, Umberto Vitolo

Blood (2008) 112 (11): 2828.

https://doi.org/10.1182/blood.V112.11.2828.2828

Published: 2008

Journal Articles

Survival Impact of Rituximab Combined to ACVBP (R-ACVBP) in 209 Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Upfront High-Dose Consolidative Autotransplantation (HDC) : A GELA Phase II Study

Christian Gisselbrecht, Olivier Fitoussi, Karim Belhadj, Nicolas Mounier, MD, Pierre Feugier, MD, Bertrand Coiffier, Christian Recher, M.D., Ph.D, Olivier Casasnovas, MD, Catherine Sebban, MD, Christophe Ferme, MD, Josette Briere, Herve Tilly, MD, Corinne Haioun

Blood (2008) 112 (11): 771.

https://doi.org/10.1182/blood.V112.11.771.771

Published: 2008

Journal Articles

Outcome of Refractory or Relapsed Patients after Front-Line Treatment for Hodgkin Lymphoma (HL): Experience of a Single Institution

Francesca Fioritoni, MD, Francesco Angrilli, MD, Simona Falorio, MD, Stella Santarone, MD, Giuseppe Fioritoni

Blood (2008) 112 (11): 4959.

https://doi.org/10.1182/blood.V112.11.4959.4959

Published: 2008

Journal Articles

Rituximab Combined to ACVBP (R-ACVBP) Supported by Pegfilgrastim as a New Inductive Treatment Followed by High-Dose Consolidative Autotransplantation (HDC) for Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) in First-Line. Results of LNH 03–39B. A GELA Study.

Karim Belhadj, MD, Jean-Philippe Jais, MD, Pierre Feugier, MD, Christian Gisselbrecht, MD, Christian Recher, MD, Olivier Casasnovas, MD, Bertrand Coiffier, MD, Catherine Sebban, MD, Alain Delmer, MD, Franck Morschhauser, MD, Daniele Canioni, MD, Herve Tilly, MD, Corinne Haioun, MD

Blood (2007) 110 (11): 3437.

https://doi.org/10.1182/blood.V110.11.3437.3437

Published: 2007

NARROW

GATA2 -Dependent Developmental and Regenerative Networks

Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): High Efficacy of High Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC auto-SCT). A Study of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Role of Consolidation High Dose Chemotherapy (HDC) with Autologous Stem Cell Transplant (ASCT) Support in Patients with Peripheral T-Cell Lymphoma Who Achieved Complete Remission (CR1) Following First Line Induction Chemotherapy

Double Epigenetic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma

GATA2 Expression Level in Chronic Myeloid Leukemia (CML) Patients Correlates with Their Prognostic Scores and Is Associated with Disease Stage at Diagnosis

R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma

Brentuximab Vedotin (BV) Does Not Impair Autologous Peripheral Blood Stem Cell Mobilization and Collection in Refractory/Relapsed CD30+ Lymphoma Patients Undergoing High-Dose Chemotherapy and Autologous Stem Cell Transplant (HDC-ASCT)

Voriconazole (VRCZ) Versus Itraconazole (ITCZ) As Antifungal Prophylaxis For Acute Myelogenus Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Patients In Induction Therapy, Prospective Randomized Study

Natural killer–cell differentiation by myeloid progenitors

Gemcitabine, Busulfan and Melphalan (GemBuMel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity In Refractory Hodgkin's Lymphoma (HL) Patients Receiving An Autologous Stem-Cell Transplant (ASCT): A Contemporaneous Comparison with BEAM and Busulfan/Melphalan (BuMel)

Blastoid Variant of Mantle Cell Lymphoma (MCL) Is Associated with P53 Abnormalities and Have a Shorter Progression-Free Survival (PFS) and Overall Survival (OS) Despite Upfront Chemo-Immunotherapy Followed by High Dose Chemotherapy and Autologous Stem Cell Support (HDC-ASCS)

Mantle Cell International Prognostic Index (MIPI) Is a Strong Predictor of the Outcome of Mantle Cell Lymphoma (MCL) in the Rituximab (R) Era.

The Effects of Rituximab Added to Front-Line or Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing High-Dose Chemotherapy (HDC) and Autologous Stem Cell Transplant (ASCT).

Identification of a Myeloid Pathway of NK Cell Development and a Myeloid- NK Cell Precursor

Validation of Mantle Cell International Prognostic Index (MIPI) in Mantle Cell Lymphoma (MCL) in a Retrospective Single Institution Series

Survival Impact of Rituximab Combined to ACVBP (R-ACVBP) in 209 Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Upfront High-Dose Consolidative Autotransplantation (HDC) : A GELA Phase II Study

Outcome of Refractory or Relapsed Patients after Front-Line Treatment for Hodgkin Lymphoma (HL): Experience of a Single Institution

Rituximab Combined to ACVBP (R-ACVBP) Supported by Pegfilgrastim as a New Inductive Treatment Followed by High-Dose Consolidative Autotransplantation (HDC) for Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) in First-Line. Results of LNH 03–39B. A GELA Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only